PMID- 15921795
OWN - NLM
STAT- MEDLINE
DCOM- 20050927
LR  - 20110608
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 7
IP  - 4
DP  - 2005 Jun
TI  - A direct comparison of the natriuretic peptides and their relationship to 
      survival in chronic heart failure of a presumed non-ischaemic origin.
PG  - 557-65
AB  - The natriuretic peptides have been validated as sensitive and specific markers of 
      left ventricular dysfunction; brain natriuretic peptide (BNP), N-terminal atrial 
      natriuretic peptide (NT-proANP) and N-terminal brain natriuretic peptide 
      (NT-proBNP) elevations have been associated with New York Heart Association 
      (NYHA) Class I-IV heart failure. We directly compared the association of each of 
      these markers with 1-year survival in 173 patients with chronic heart failure of 
      a presumed nonischaemic origin entering the PRAISE-2 Trial, a clinical study 
      which assessed the therapeutic effect of Amlodipine in patients with NYHA Class 
      III and IV heart failure and a left ventricular ejection fraction (LVEF) <30%. 
      BNP, NT-proBNP, and NT-proANP levels were all correlated with 1-year mortality by 
      univariate Cox proportional hazards analyses. With respect to multivariate Cox 
      proportional hazards regression models containing variables deemed significant in 
      univariate analyses, NT-proANP alone was identified as an independent predictor 
      of 1-year mortality when log-transformed continuous covariates were utilized in 
      the analysis. When the analysis was repeated using dichotomous covariates, 
      NT-proANP remained the most significant predictor of 1-year mortality, followed 
      by NT-proBNP, NYHA classification and BNP. We conclude that all three natriuretic 
      peptides are significant predictors of short-term mortality in subjects with 
      chronic congestive heart failure (CHF) of a presumed nonischaemic origin. Larger 
      prospective studies are required to validate the clinical utility of NT-proANP as 
      a discriminating marker of short-term survival, and to validate proposed cutoffs 
      of approximately 2300 pmol/l for NT-proANP, 1500 pg/ml for NT-proBNP, and 50 
      pmol/l for BNP as prognostic indicators of adverse short-term outcome.
FAU - Stanton, Eric
AU  - Stanton E
AD  - McMaster University, St. Joseph's Hospital, 50 Charlton Avenue East, Hamilton, 
      ON, Canada L8N 4A6. stantone@mcmaster.ca
FAU - Hansen, Mark
AU  - Hansen M
FAU - Wijeysundera, Hairinda C
AU  - Wijeysundera HC
FAU - Kupchak, Peter
AU  - Kupchak P
FAU - Hall, Christian
AU  - Hall C
FAU - Rouleau, Jean L
AU  - Rouleau JL
CN  - PRAISE-2 study investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Aged
MH  - Atrial Natriuretic Factor/*blood
MH  - Female
MH  - Heart Failure/*blood/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Proportional Hazards Models
MH  - ROC Curve
MH  - Survival Analysis
MH  - Ventricular Dysfunction, Left/blood
EDAT- 2005/06/01 09:00
MHDA- 2005/09/28 09:00
CRDT- 2005/06/01 09:00
PHST- 2003/09/04 00:00 [received]
PHST- 2004/05/12 00:00 [revised]
PHST- 2004/06/27 00:00 [accepted]
PHST- 2005/06/01 09:00 [pubmed]
PHST- 2005/09/28 09:00 [medline]
PHST- 2005/06/01 09:00 [entrez]
AID - S1388-9842(04)00213-2 [pii]
AID - 10.1016/j.ejheart.2004.06.004 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2005 Jun;7(4):557-65. doi: 10.1016/j.ejheart.2004.06.004.